Abstract Parkinson’s disease (PD) is an age-related neurodegenerative disorder which is assessed based on the motor symptoms. A number of microRNAs (miRNAs) are dysregulated and involved in the pathogenesis or development of PD. However, no confirmed markers are used for the early detection of PD. The present study aimed to elucidate the potential two miRNAs (miR-132-3p and miR-146-5p) as novel markers for early PD diagnosis. In the present study, the expression levels of miR-132-3p and miR-146-5p in serum samples from 82 patients with PD and 44 healthy volunteers were measured by reverse transcription-quantitative polymerase chain reaction. Furthermore, the correlation analysis was performed between aberrant miRNAs and Braak staging, Part V of the Unified Parkinson’s Disease Rating Scale (UPDRS-V; the modified Hoehn and Yahr staging of PD) and Part III of the UPDRS-III. Subsequently, the receiver–operating characteristic (ROC) curve results of miR-132-3p and miR-146-5p from healthy volunteers for PD prediction and from severe PD patients were assessed. From the results it was observed that miR-132-3p and miR-146a-5p expressions were significantly decreased in the serum samples of patients with PD compared to those in the healthy volunteers. Moreover, the expressions of miR-132-3p and miR-146a-5p showed a dramatic decrease in severe PD patients as compared to the normal PD patients. Meanwhile, miR-132-3p and miR-146-5p expressions were negatively correlated with Braak staging (r = −0.45, P < 0.0001; r = −0.51, P < 0.0001), UPDRS-III (r = −0.55, P < 0.0001; r = −0.51, P < 0.0001) and UPDRS-V scores (r = − 0.46, P < 0.0001; r = −0.45, P < 0.0001) in PD patients. The area under the curve (AUC) results of miR-132-3p and miR-146a-5p in discriminating PD patients from the healthy controls were 0.7325 (95% CI = 0.6400–0.8251) and 0.7295 (95% CI = 0.3658–0.8232). Moreover, the AUC results of miR-132-3p and miR-146-5p concerning discriminating severe PD patients from normal PD patients were 0.8175 (95% CI = 0.7229–0.9121) and 0.7921 (95% CI = 0.6937–0.8905). In other words, both miR-132-3p and miR-146a-5p may function as promising biomarkers for early diagnosis of PD.

中文翻译：

---

帕金森病患者 microRNA-132-3p 和 microRNA-146a-5p 的异常表达

摘要 帕金森病 (PD) 是一种与年龄相关的神经退行性疾病，根据运动症状进行评估。许多 microRNA (miRNA) 失调并参与 PD 的发病机制或发展。然而，没有确认的标记用于早期检测 PD。本研究旨在阐明潜在的两种 miRNA（miR-132-3p 和 miR-146-5p）作为早期 PD 诊断的新标志物。在本研究中，通过逆转录-定量聚合酶链反应测量了 82 名 PD 患者和 44 名健康志愿者的血清样本中 miR-132-3p 和 miR-146-5p 的表达水平。此外，在异常 miRNA 和 Braak 分期之间进行了相关性分析，统一帕金森病评定量表 (UPDRS-V; PD 的改良 Hoehn 和 Yahr 分期）和 UPDRS-III 的第三部分。随后，评估了来自健康志愿者和严重 PD 患者的 miR-132-3p 和 miR-146-5p 的受试者工作特征（ROC）曲线结果，用于 PD 预测。结果表明，与健康志愿者相比，PD患者血清样本中miR-132-3p和miR-146a-5p的表达显着降低。此外，与正常 PD 患者相比，miR-132-3p 和 miR-146a-5p 在严重 PD 患者中的表达显着降低。同时，miR-132-3p和miR-146-5p的表达与Braak分期呈负相关（r = -0.45，P < 0.0001；r = -0.51，P < 0.0001），UPDRS-III（r = -0.55，P < 0.0001；r = -0.51，P < 0.0001）和 UPDRS-V 评分（r = - 0.46，P < 0.0001；r = -0.45, P < 0.0001) 在 PD 患者中。miR-132-3p 和 miR-146a-5p 区分 PD 患者与健康对照的曲线下面积 (AUC) 结果分别为 0.7325 (95% CI = 0.6400-0.8251) 和 0.7295 (95% CI = 0.3652-0.823) ）。此外，miR-132-3p 和 miR-146-5p 在区分严重 PD 患者与正常 PD 患者方面的 AUC 结果分别为 0.8175（95% CI = 0.7229-0.9121）和 0.7921（95% CI = 0.6937-0.8905）。换句话说，miR-132-3p 和 miR-146a-5p 都可以作为 PD 早期诊断的有希望的生物标志物。miR-132-3p 和 miR-146-5p 区分严重 PD 患者与正常 PD 患者的 AUC 结果分别为 0.8175（95% CI = 0.7229–0.9121）和 0.7921（95% CI = 0.6937–0.8905）。换句话说，miR-132-3p 和 miR-146a-5p 都可以作为 PD 早期诊断的有希望的生物标志物。miR-132-3p 和 miR-146-5p 区分严重 PD 患者与正常 PD 患者的 AUC 结果分别为 0.8175（95% CI = 0.7229–0.9121）和 0.7921（95% CI = 0.6937–0.8905）。换句话说，miR-132-3p 和 miR-146a-5p 都可以作为 PD 早期诊断的有希望的生物标志物。